Verified peer comparison

CVS vs ABBV

CVS Health Corporation compared with AbbVie Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

CVS

CVS Health Corporation

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

ABBV

AbbVie Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

CVS: Health Care Services

ABBV: Biotechnology

Upside lens

CVS: Pricing, benefit redesign and membership actions can improve alignment between premiums and medical costs. Insurance, PBM, pharmacy and care-delivery assets can coordinate access and lower total care costs. Retail and specialty pharmacy scale can support purchasing economics and recurring prescription relationships.

ABBV: Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry. Growth across Vraylar, Botox Therapeutic, the migraine portfolio, and Vyalev broadens AbbVie's growth base beyond immunology. Regulatory submissions, approvals, and key clinical data readouts expected over the next year could add indications and reinforce the post-Humira portfolio transition.

Risk lens

CVS: Higher utilization or acuity can outpace pricing and pressure insurance margins. Rebate, transparency and pharmacy-reimbursement reforms could alter Caremark economics. Leverage and complexity across acquired care assets can limit capital flexibility and delay returns.

ABBV: Humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition. Imbruvica declines are weighing on oncology, requiring growth from Venclexta, Elahere, and pipeline assets to offset the mature brand. U.S. drug-pricing policy, including the selection of Botox for Medicare negotiated prices beginning in 2028, could pressure future revenue and margins.